NS Pharma, Inc., a wholly owned subsidiary of Nippon Shinyaku Co., Ltd., announced that new, long-term efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO® injection will be presented at the PPMD 2021 Annual Conference being held virtually from June 23-26.
May 12, 2021
· 2 min read